TapewireFind a company

person · Reporting owner

Gaslightwala Abizer

Disclosed activity across 1 company

Tapewire entity
35441
SEC CIK
0002049375

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Akari Therapeutics PlcAKTX · Entity 7692Director · CEOSeptember 29, 2026October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akari Therapeutics Plc

Report date September 29, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
American Depositary Shares representing Ordinary SharesSEC Table I · non-derivativeDirect14,107 Reported balance After 2026-09-29 transaction · row 1
1 source row

Row 1 · 2026-09-29 · Grant · Acquired 6,430 · Balance 14,107

F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan.

Filing footnotes · ownership attribution and instrument terms

F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 29, 2026 Filed Oct 2, 2026 00:50 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depositary Shares representing Ordinary Shares 6,430 $9.72 $62,499.60
Disclosure

SEC source: 0001493152-26-045366 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,107

F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 00:04 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantStock Option (Right to Buy) · Derivative 15,563 $0.00 Strike: $14.63 $0.00
Disclosure

SEC source: 0001493152-26-030207 · ownership.xml · derivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,563

Underlying: American Depositary Shares representing Ordinary Shares · 15,563 shares

Expires 2036-06-24

Read SEC document
June 24, 2026 Filed Jun 26, 2026 00:04 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantStock Option (Right to Buy) · Derivative 5,500 $0.00 Strike: $4.64 $0.00
Disclosure

SEC source: 0001493152-26-030207 · ownership.xml · derivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: American Depositary Shares representing Ordinary Shares · 5,500 shares

Expires 2036-04-01

F1 · balance_after: On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares.

Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:56 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchasePre-Funded Warrants to purchase ADRs · Derivative 773,323 $0.40 Strike: $0.00 $312,499.82
Disclosure

SEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 4

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 773,323

Underlying: American Depositary Shares representing Ordinary Shares · 773,323 shares

Expires not disclosed

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").

F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001

F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").

F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:56 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseWarrants to purchase ADRs · Derivative 773,323 Not disclosed Strike: $0.39 Not disclosed
Disclosure

SEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 3

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 773,323

Underlying: American Depositary Shares representing Ordinary Shares · 773,323 shares

Expires not disclosed

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").

F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").

F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:56 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchasePre-Funded Warrants to purchase ADRs · Derivative 309,328 $0.40 Strike: $0.00 $124,999.44
Disclosure

SEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,328

Underlying: American Depositary Shares representing Ordinary Shares · 309,328 shares

Expires not disclosed

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001

F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

Read SEC document
December 16, 2025 Filed Dec 19, 2025 02:56 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative 309,328 Not disclosed Strike: $0.39 Not disclosed
Disclosure

SEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,328

Underlying: American Depositary Shares representing Ordinary Shares · 309,328 shares

Expires not disclosed

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

Read SEC document
August 25, 2025 Filed Aug 29, 2025 20:55 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 3,000 $0.90 $2,700.00
Disclosure

SEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 3

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,574

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

Read SEC document
August 22, 2025 Filed Aug 29, 2025 20:55 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 8,000 $0.93 $7,440.00
Disclosure

SEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,574

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.92 to $0.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

Read SEC document
August 21, 2025 Filed Aug 29, 2025 20:55 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 10,000 $0.94 $9,400.00
Disclosure

SEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,574

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.94, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

Read SEC document
June 24, 2025 Filed Jun 25, 2025 20:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 5,203 $1.16 $6,035.48
Disclosure

SEC source: 0000950170-25-089976 · ownership.xml · nonDerivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,574

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.

Read SEC document
June 23, 2025 Filed Jun 25, 2025 20:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 943 $1.15 $1,084.45
Disclosure

SEC source: 0000950170-25-089976 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 272,371

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
June 20, 2025 Filed Jun 24, 2025 20:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 10,000 $1.20 $12,000.00
Disclosure

SEC source: 0000950170-25-089462 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
June 17, 2025 Filed Jun 20, 2025 20:05 UTC Akari Therapeutics Plc AKTX · Entity 7692 PurchaseAmerican Depositary Shares representing Ordinary Shares 15,000 $1.20 $18,000.00
Disclosure

SEC source: 0000950170-25-088490 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
June 13, 2025 Filed Jun 16, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depositary Shares representing Ordinary Shares 25,000 $1.19 $29,750.00
Disclosure

SEC source: 0000950170-25-086829 · ownership.xml · nonDerivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 246,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F3 · kind: On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS.

F3 · price: On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS.

Read SEC document
June 12, 2025 Filed Jun 16, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depositary Shares representing Ordinary Shares 20,000 $1.23 $24,600.00
Disclosure

SEC source: 0000950170-25-086829 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · kind: On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS.

F2 · price: On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depositary Shares representing Ordinary Shares 20,000 $1.27 $25,400.00
Disclosure

SEC source: 0000950170-25-085472 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · kind: On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS.

F2 · price: On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantStock Option (Right to Buy) · Derivative 600,000 $0.00 Strike: $1.50 $0.00
Disclosure

SEC source: 0000950170-25-043933 · ownership.xml · derivative · entry 3

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: American Depositary Shares representing Ordinary Shares · 600,000 shares

Expires 2035-03-20

F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantStock Option (Right to Buy) · Derivative 1,100,000 $0.00 Strike: $1.50 $0.00
Disclosure

SEC source: 0000950170-25-043933 · ownership.xml · derivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,100,000

Underlying: American Depositary Shares representing Ordinary Shares · 1,100,000 shares

Expires 2035-03-20

F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
March 06, 2025 Filed Mar 10, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantSeries B Warrants (Right to Buy) · Derivative 133,928 $1.12 Strike: $0.87 $149,999.36
Disclosure

SEC source: 0000950170-25-036483 · ownership.xml · derivative · entry 3

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,928

Underlying: American Depositary Shares representing Ordinary Shares · 133,928 shares

Expires 2030-03-06

F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
March 06, 2025 Filed Mar 10, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantSeries A Warrants (Right to Buy) · Derivative 133,928 $1.12 Strike: $0.87 $149,999.36
Disclosure

SEC source: 0000950170-25-036483 · ownership.xml · derivative · entry 2

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,928

Underlying: American Depositary Shares representing Ordinary Shares · 133,928 shares

Expires 2026-03-06

F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

Read SEC document
March 06, 2025 Filed Mar 10, 2025 21:00 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depositary Shares representing Ordinary Shares 133,928 $1.12 $149,999.36
Disclosure

SEC source: 0000950170-25-036483 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,428

F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 13:05 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depository Shares representing Ordinary Shares 11,439 $1.22 $13,955.58
Disclosure

SEC source: 0000950170-25-004580 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,860

F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · kind: On January 10, 2025, the Reporting Person acquired 11,439 ADS at purchase price of $1.22 per ADS.

F2 · price: On January 10, 2025, the Reporting Person acquired 11,439 ADS at purchase price of $1.22 per ADS.

Read SEC document
January 10, 2025 Filed Feb 7, 2025 21:30 UTC Amendment Akari Therapeutics Plc AKTX · Entity 7692 GrantAmerican Depository Shares representing Ordinary Shares 11,640 $1.22 $14,200.80
Disclosure

SEC source: 0000950170-25-016334 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,500

F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

F2 · kind: On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS.

F2 · price: On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 21:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantOrdinary Shares, par value $0.0001 per share 1,720,000 $0.00 $1,032.00
Disclosure

SEC source: 0000950170-25-002865 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,720,000

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

F2 · kind: On January 3, 2025, the Reporting Person acquired 1,720,000 Ordinary Shares at purchase prices ranging from of $0.00064 to $0.000625 per Ordinary Share.

F2 · price: On January 3, 2025, the Reporting Person acquired 1,720,000 Ordinary Shares at purchase prices ranging from of $0.00064 to $0.000625 per Ordinary Share.

Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantOrdinary Shares, par value $0.0001 per share 40,000,000 $0.00 $20,000.00
Disclosure

SEC source: 0000950170-24-141158 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000,000

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

F2 · kind: On December 27, 2024, the Reporting Person acquired 40,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share.

F2 · price: On December 27, 2024, the Reporting Person acquired 40,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share.

Read SEC document
December 26, 2024 Filed Dec 27, 2024 21:30 UTC Akari Therapeutics Plc AKTX · Entity 7692 GrantOrdinary Shares, par value $0.0001 per share 30,000,000 $0.00 $15,000.00
Disclosure

SEC source: 0000950170-24-140808 · ownership.xml · nonDerivative · entry 1

Gaslightwala Abizer · CIK 0002049375 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000,000

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

F2 · kind: On December 26, 2024, the Reporting Person acquired 30,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share.

F2 · price: On December 26, 2024, the Reporting Person acquired 30,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.